Immunotherapy
In experimental glioma, interstitial transfer factor is effective adjuvant immunotherapy
Published in Vaccine Weekly, March 22nd, 2006
"Glioblastoma multiform (GBM) is the most common tumor of the central nervous system in humans. Unfortunately its prognosis is poor and because of the lack of efficacious therapies, immunotherapy is a potential treatment. Transfer factors (TF) are low molecular weight dialyzable products extracted from immune cells which transmit the ability to express delayed-type hypersensitivity and cell mediated immunity from sensitized donors to nonimmune recipients. In this study, we determined the efficacy of TF as immunotherapy to treat experimental glioblastoma. We used TF obtained from...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-03-22)
More Articles from Vaccine Weekly
- Breast Cancer Vaccine
Breast cancer prognostic information is aided by monocyte chemotactic protein-1 - Chlamydia Vaccine
Chlamydia protection is better delivered by intranasal than transcutaneous vaccine - Escherichia Coli Vaccine
E. coli O157O-specific vaccine is safe and immunogenic in children - Rotavirus Vaccine
Economics of rotavirus gastroenteritis and vaccine in Europe are focus of review - Tuberculosis Vaccine
Tuberculosis vaccine efficacy is affected by BCG strain and delivery route - Amebiasis Vaccine
Amebiasis vaccine is developed that blocks adherence - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
